The GNL Selectors

Pick the three priorities that matter most. We surface the top three options the evidence supports for your context. Grace carries the depth.

Ask Grace

Want to walk a selector with Grace at your side, in the GNL app?

How a selector works

Every selector follows the same shape. You name the situation; you pick three priorities from eight; the algorithm scores the options in the GNL evidence base against your picks; we surface the top three for the conversation you are about to have with your diabetes team.

  1. Type and age band. Diabetes type is pre-selected from your profile if you have one. Age band you pick every session, because age routes clinical decisions through bands, not birthdays.
  2. Three priorities. Eight chips per family. Pick the three that matter most to you, not three the algorithm thinks should matter. The whole point of the selector is that you decide.
  3. Top three. Three options with a fill bar showing how each fits your picks. Tap any result to open Grace, who teaches you the evidence behind the choice and points you back to your care team for the decision.

What is live, what is coming

Six selector families ship across v1 and v1.5. CGM and AID are live in the app right now. The other four were drafted across May 2026 and ship together when the BGM accuracy data fills the last evidence gap.

CGM selector (live)

Continuous glucose monitors. Nine UK systems scored against eight priorities: AID and pump integration, smallest and most discreet form factor, alarm sophistication, paediatric use, optional calibration, longest wear time, predictive and AI features, integration with apps and smart pens, follower and remote monitoring, customer support.

Anchored on the Pemberton 2026 framework paper (Diabetes, Obesity and Metabolism, doi:10.1111/dom.70460, open access). The accuracy lens reads transparency, IFCC-derived standardisation, and the A-P-B calibration alignment model. The selector reads through to per-device entity pages on the GNL site.

Foundational guide: CGM guide hub. Advanced: AID hub for how the CGM choice meets the pump algorithm.

AID selector (live)

Automated insulin delivery systems. Five UK-procurable systems on the matrix: Medtronic 780G, Ypsomed mylife with CamAPS FX, Insulet Omnipod 5, Tandem t:slim X2 with Control-IQ, Tandem Mobi with Control-IQ+. Scored against eight priorities: CGM flexibility, tubeless form factor, algorithm control and customisation, lowest glucose target, fewest manual settings, paediatric suitability, IOB visibility, additional features.

The AID Optimiser ladder is the GNL educational synthesis that sits behind the selector. Reviewed with input from CamAPS, MiniMed, Tandem and Insulet medical leads. Not endorsed by any of them. Grade D synthesis on a Grade A and B evidence base, with a declared subjective bias toward IOB visibility and the IOB-vs-algorithm-strength trade-off.

Foundational guide: AID hub. Advanced: AID Optimiser, the strength-ladder explorer.

BGM selector (v1 build, BGM accuracy in flight)

Blood glucose meters. The selector ranks UK-commissioned meters across eight priorities: ISO 15197 compliance, accuracy in the 5/5 and 10/10 and 15/15 bands, small sample volume, no-coding calibration, glucose dehydrogenase chemistry, NHS commissioning per PRN00037.

Accuracy bands follow the framework Pemberton 2026 carries from CGM into BGM: 15/15 is the ISO 15197 floor; 10/10 is closer to the precision insulin dosing depends on; 5/5 is the band that matters most when glucose is changing rapidly, particularly in the paediatric and adolescent type 1 cohorts. The landmark Klonoff 2018 study (Diabetes Care 41:1681-1688, doi:10.2337/dc17-1960) is the independent comparator: six of 18 marketed meters met the predetermined accuracy standard in all three studies; four met it in none.

Foundational guide: CGM guide hub covers the accuracy framework that translates to BGM.

Insulin selector (v1 build, rapid-acting first)

UK rapid-acting analogue insulins in v1 (the point of choice most users have most often). Intermediate, long-acting basal, and pre-mixed insulins land in v1.5. Eight priorities: action class, onset time, concentration safety (U-100 vs U-200 vs U-300), half-unit dosing, pen device family, pregnancy compatibility, NHS prescription pathway, biosimilar status.

UK formulary anchored on the DSN Forum UK insulin types and pen devices reference. Concentration safety is the load-bearing chip: pen-to-pen swap between U-100 and U-200 lispro, or between Lantus and Toujeo, is a known hazard; the selector surfaces this where it matters.

Foundational guide: IOB guide hub covers how insulin action time interacts with dosing decisions.

GLP-1 and injectables selector (v1 build)

UK GLP-1 receptor agonists and dual GLP-1 plus GIP agonists per MHRA public guidance (last updated 5 February 2026). Five agents in v1: semaglutide subcutaneous (Wegovy and Ozempic), semaglutide oral (Rybelsus), tirzepatide (Mounjaro), liraglutide (Victoza and Saxenda), dulaglutide (Trulicity). Eight priorities: licensed indication, dosing frequency, delivery route, cardiovascular outcome benefit, renal compatibility, weight loss potency, pregnancy washout, NHS access route.

Class hierarchy on weight loss runs tirzepatide above semaglutide above liraglutide above dulaglutide. MHRA regulatory overlay surfaces the pregnancy hard exclusion with washout periods per agent, the tirzepatide oral-contraceptive interaction, the NAION rare-event alert on semaglutide, and the buying-online safety messaging.

Type 1 diabetes use is off-label and signposted to the diabetes care team only. The selector does not present GLP-1 in T1D as a treatment a user can self-select. Foundational reading: MHRA gov.uk on GLP-1 medicines for weight loss and diabetes (open access).

Orals (type 2) selector, interim v1

SGLT-2 inhibitors carry the full per-agent comparison in v1 (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin). Metformin and DPP-4 inhibitors sit as signpost cards in v1; the full per-agent chip-set for metformin, DPP-4, sulphonylureas, and thiazolidinediones lands in v1.5 once UK brand-by-brand comparison data is filed.

Eight priorities: cardiovascular outcome trial benefit, paediatric licensing, chronic kidney disease indication, heart failure indication, dose range and flexibility, weight loss effect, lower DKA risk, lower genitourinary infection risk. NICE NG28 is the UK first-line decision-tree anchor; ADA and EASD 2022 consensus carries the international class framework.

Foundational reading: hyperglycaemia hub for the safety overlay; the orals decision tree itself lives in NICE NG28 (linked from the selector result cards).

One selector, one decision, three picks. The selectors are starting points for the conversation with your diabetes team, not prescriptions. The selector surfaces options the evidence supports for your stated priorities. The decision about which option fits your day sits with you and your team.

Where the depth lives

The selectors are doors. The depth behind each chip lives in the GNL guide cluster.

  • CGM guide. Accuracy frameworks, calibration, alarms, follower support, paediatric use.
  • AID guide hub. Systems, algorithms, exercise mode, paediatric floors, IOB visibility.
  • AID Optimiser. Algorithm strength ladder, level-by-level walk-through.
  • IOB guide. How devices calculate insulin on board, what it means for your day.
  • Exercise guide. Pre-bolus reductions, activity types, post-exercise late-onset hypo.
  • Hypoglycaemia guide. Causes, treatment, prevention.
  • Hyperglycaemia guide. Causes, treatment, ketones, sick-day rules.
  • Alcohol guide. How alcohol interacts with insulin, carbohydrate, and exercise.
  • Grace. The AI layer that carries the depth behind every selector chip.

Population vs individual

Every published accuracy figure, every weight-loss number, every cardiovascular outcome is a population-mean. Your individual experience varies on every axis the selector does not name: insulin absorption, illness, menstrual cycle, dawn phenomenon, stress, sleep architecture, where you live, what you eat, who you eat with.

The selector surfaces the population view. The diabetes care team helps interpret your individual pattern. When the selector says one option fits your picks, that is the starting point of a clinical conversation, not the end of it.

Take the selectors with you

Open Grace in the GNL app

Open the app CGM guide AID guide

Sources

Pemberton JS et al. International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoring. Diabetes, Obesity and Metabolism. 2026;28(4):2551-2565. doi:10.1111/dom.70460. Open access.

Klonoff DC et al. Investigation of the accuracy of 18 marketed blood glucose monitors available to purchase. Diabetes Care. 2018;41(8):1681-1688. doi:10.2337/dc17-1960.

Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes, what you need to know. UK government public guidance, last updated 5 February 2026.

NHS England. Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets. PRN00037 v3, 18 November 2024.

National Institute for Health and Care Excellence. NG28 visual summary: choosing medicines for first-line and further treatment in adults with type 2 diabetes.

Davies MJ et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2022;65:1925-1966. doi:10.1007/s00125-022-05787-2.

Full evidence base: Grace carries every citation behind every selector chip.

Ask Grace